EUVIMEDEUVIMED entdecken
Crossref

Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case–control study

Mustafa Esen, Abdullah Demirbaş, Esin Diremsizoglu

Archives of Dermatological Research · 17.04.2025 · 317 (1)

DOI: 10.1007/s00403-025-04231-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Dermatological Research, online erschienen am 17.04.2025. Verfasst von Mustafa Esen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine Hospital, Dicle University, Diyarbakır, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Quality of Life, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic spontaneous urticaria (CSU) impacts both physical and mental well-being, causing distress and sleep disturbances. While omalizumab reduces disease activity, its effects on mental health and quality of life remain unclear. This study assesses the psychosocial burden and sleep disturbances in CSU patients receiving omalizumab compared to healthy controls and explores their relationship with disease parameters. This case--control study included 210 CSU patients receiving omalizumab for at least three months and 210 age- and sex-matched healthy controls. Disease severity was assessed using the Urticaria Activity Score over 7 Days (UAS7) and Urticaria Control Test (UCT), while quality of life was evaluated with the Chronic Urticaria Quality of Life Questionnaire (CU-Q₂oL). Psychological distress and sleep disturbances were measured using validated scales, including the Perceived Stress Scale (PSS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). CSU patients had significantly higher scores for perceived stress, depression, anxiety, and daytime sleepiness compared to controls (p < 0.001). Patients with a good response to omalizumab also showed significantly higher psychological distress and poorer sleep quality than controls (p < 0.001). Omalizumab response was good in 29.5%, moderate in 38.6%, and limited in 31.9% of patients. Despite treatment, 32.9% reported no change in quality of life, while 35.7% had mild and 31.4% had moderate improvement. A history of atopic disease was present in 55.7% of patients, who had significantly higher daytime sleepiness scores than those without (p = 0.045). In CSU patients, while omalizumab improves symptoms and quality of life, psychological distress persists in substantial subsets, highlighting the need to address mental health and lifestyle factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabQuality of LifeChronic UrticariaAnti-Allergic AgentsSleep Wake DisordersHumansFemaleMaleCase-Control StudiesAdultMiddle AgedSeverity of Illness IndexSurveys and QuestionnairesAnxietySleepStress, PsychologicalYoung AdultMental HealthDepressionAgedTreatment OutcomePsychological Well-Being

Stichwörter der Autor:innen

AnxietyChronic urticariaOmalizumabPsychosocial factorsQuality of life

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Faculty of Medicine Hospital, Dicle University, Diyarbakır, Turkey.
  • Department of Dermatology, Faculty of Medicine Hospital, Kocaeli University, Kocaeli, Turkey.
  • Department of Dermatology, Faculty of Medicine Hospital, Kocaeli University, Kocaeli, Turkey. mdesinarslan@gmail.com.

Zitieren

APA

Esen, M., Demirbaş, A., & Diremsizoglu, E. (2025). Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case–control study. Archives of Dermatological Research, 317(1). https://doi.org/10.1007/s00403-025-04231-w

Vancouver

Esen M, Demirbaş A, Diremsizoglu E. Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case–control study. Archives of Dermatological Research. 2025;317(1). doi:10.1007/s00403-025-04231-w

BibTeX
@article{Esen2025,
  author = {Esen, Mustafa and Demirbaş, Abdullah and Diremsizoglu, Esin},
  title = {Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case–control study},
  journal = {Archives of Dermatological Research},
  year = {2025},
  volume = {317},
  number = {1},
  doi = {10.1007/s00403-025-04231-w}
}
Kostenlos starten →